Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Author's Avatar
May 13, 2022

- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities